文献速递创伤与烧伤复苏、休克与脓毒症

冷沉淀在大量输血创伤患者中的作用:创伤质量改进计划数据库结果可能改变你的看法

The role of cryoprecipitate in massively transfused patients: Results from the Trauma Quality Improvement Program database may change your mind.
PubMed 文献 · J Trauma Acute Care Surg · 2020-01-01
一句话结论创伤质量改进计划数据库分析提示,大量输血创伤患者早期使用冷沉淀可能与住院死亡率降低相关,但需进一步研究。

该研究基于美国外科医师学会创伤质量改进计划2015-2016年数据,纳入所有4小时内接受4单位及以上浓缩红细胞(pRBC)的成人创伤患者,按24小时内是否接受冷沉淀分为两组。共纳入19643例(冷沉淀组4945例,无冷沉淀组14698例),总体并发症率45%,死亡率47%,29%的患者在24小时内死亡。冷沉淀组血浆和pRBC输注量更低(p<0.01),24小时死亡率和住院死亡率更低(p<0.01),但并发症发生率(p=0.36)和血小板输注量(p=0.22)无差异。多因素logistic回归显示冷沉淀使用与住院死亡率降低相关(OR 0.79 [0.77-0.87];p=0.01),与并发症无关(OR 1.48 [0.71-1.99];p=0.31)。作者结论认为冷沉淀辅助使用可能降低死亡率而不影响并发症和输血需求,需进一步研究。

要点

  • 在4小时内接受≥4单位pRBC的成人创伤患者中,24小时内使用冷沉淀与住院死亡率降低相关(OR 0.79 [0.77-0.87];p=0.01)。
  • 冷沉淀组24小时死亡率和住院死亡率均更低(p<0.01),但两组并发症发生率无差异(p=0.36)。
  • 冷沉淀组血浆和pRBC输注量更低(p<0.01),血小板输注量无差异(p=0.22)。
  • 线性回归显示冷沉淀使用与24小时pRBC、血浆、血小板输注需求均无关(p值分别为0.47、0.29、0.17)。
  • 作者结论认为冷沉淀辅助使用可能降低死亡率而不影响并发症和输血需求,需进一步研究。

适用人群与场景

  • 美国外科医师学会创伤质量改进计划数据库中2015-2016年收治的成人创伤患者,且4小时内接受4单位及以上浓缩红细胞(pRBC)。

研究设计与关键结果

  • 研究类型为基于美国外科医师学会创伤质量改进计划数据库的2年(2015-2016年)分析,共纳入19643例成人创伤患者(冷沉淀组4945例,无冷沉淀组14698例)。
  • 平均年龄40±22岁,损伤严重度评分中位数27 [18-40],格拉斯哥昏迷评分中位数9 [3-14]。
  • 总体并发症率45%,死亡率47%,29%的患者在24小时内死亡。
  • 冷沉淀组血浆输注量更低(p<0.01),pRBC输注量更低(p<0.01),24小时死亡率更低(p<0.01),住院死亡率更低(p<0.01)。
  • 两组并发症发生率无差异(p=0.36),血小板输注量无差异(p=0.22)。
  • 多因素logistic回归:冷沉淀使用与住院死亡率降低相关(OR 0.78 [0.63-0.84];p=0.02),与住院并发症无关(OR 1.48 [0.71-1.99];p=0.31)。
  • 线性回归:冷沉淀使用与24小时pRBC输注需求无关(β=-0.12 [-0.28至0.27],p=0.47),与24小时血浆输注需求无关(β=-0.06 [-0.21至0.43],p=0.29),与24小时血小板输注需求无关(β=-0.24 [-0.09至0.33],p=0.17)。

证据类型、等级与局限

  • 证据类型:基于创伤质量改进计划数据库的分析;证据等级:治疗性,level IV。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者结论认为,在出血性创伤患者中辅助使用冷沉淀可能降低死亡率而不影响住院并发症和输血需求,需进一步研究以更好地理解其潜在有益效应。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Cryoprecipitate was developed for the treatment of inherited and acquired coagulopathies. The role of cryoprecipitate in hemorrhaging trauma patients is still speculative. The aim of our study was to assess the role of cryoprecipitate as an adjunct to transfusion in trauma patients.

METHODS: We performed a 2-year (2015-2016) analysis of the American College of Surgeons-Trauma Quality Improvement Program data set and included all adult trauma patients who received 4 or greater packed red blood cells (pRBCs)/4 hours. Patients were stratified based on receipt of cryoprecipitate within the first 24 hours (cryoprecipitate vs. no-cryoprecipitate). Outcomes were blood products transfused, in-hospital complications, and mortality. Regression analyses were performed.

RESULTS: A total of 19,643 (cryoprecipitate, 4,945; no-cryoprecipitate, 14,698) were included. Mean age was 40 ± 22 years, median Injury Severity Score was 27 [18-40], and Glasgow Coma Scale score was 9 [3-14]. The overall complication rate was 45%, mortality was 47%, and 29% of the patients died in the first 24 hours. Patients in the cryoprecipitate group received a lower volume of plasma (p < 0.01), and pRBCs (p < 0.01). Additionally, patients who received cryoprecipitate had lower rates of 24-hour mortality (p < 0.01) and in-hospital mortality (p < 0.01). However, there was no difference between the two groups regarding complications (p = 0.36) or volume of platelet transfused (p = 0.22). On multivariate logistic regression, the use of cryoprecipitate was associated with decreased (odds ratio [OR], 0.78 [0.63-0.84]; p = 0.02), in-hospital mortality (OR, 0.79 [0.77-0.87]; p = 0.01), but had no association with in-hospital complications (OR, 1.48 [0.71-1.99]; p = 0.31). On linear regression analysis, the use of cryoprecipitate was not associated with 24-hour pRBCs (β = -0.12 [-0.28 to 0.27], p = 0.47), 24-hour plasma (β = -0.06 [-0.21 to 0.43], p = 0.29), and 24-hour platelets (β = -0.24 [-0.09 to 0.33], p = 0.17) transfusion requirements.

CONCLUSION: The adjunctive use of cryoprecipitate in hemorrhaging trauma patients may reduce mortality without affecting in-hospital complications and transfusion requirements. Further studies are needed to better understand its potentially beneficial effects.

LEVEL OF EVIDENCE: Therapeutic, level IV.

来源:J Trauma Acute Care Surg,查看原文。版权归原作者所有。

参考来源

  1. Ditillo M, Hanna K, Castanon L, et al. The role of cryoprecipitate in massively transfused patients: Results from the Trauma Quality Improvement Program database may change your mind. J Trauma Acute Care Surg. 2020. PMID: 32355101. doi:10.1097/TA.0000000000002764

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。